 Calen Steiner
Concepts (141)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Crohn Disease | 4 | 2023 | 254 | 1.820 |
Why?
| | Receptor Protein-Tyrosine Kinases | 2 | 2024 | 231 | 1.360 |
Why?
| | Intestinal Obstruction | 2 | 2021 | 53 | 1.350 |
Why?
| | Proto-Oncogene Proteins | 2 | 2024 | 624 | 1.220 |
Why?
| | Inflammatory Bowel Diseases | 4 | 2024 | 360 | 1.040 |
Why?
| | Intestinal Mucosa | 4 | 2025 | 632 | 0.950 |
Why?
| | Intestines | 2 | 2023 | 357 | 0.770 |
Why?
| | Benzocycloheptenes | 1 | 2021 | 2 | 0.700 |
Why?
| | Triazoles | 1 | 2021 | 162 | 0.620 |
Why?
| | Wound Healing | 1 | 2022 | 350 | 0.620 |
Why?
| | Pancreatitis | 1 | 2020 | 136 | 0.600 |
Why?
| | Colitis, Ulcerative | 4 | 2024 | 143 | 0.510 |
Why?
| | Fibrosis | 4 | 2023 | 542 | 0.500 |
Why?
| | MicroRNAs | 1 | 2021 | 692 | 0.440 |
Why?
| | Constriction, Pathologic | 2 | 2021 | 241 | 0.330 |
Why?
| | Tumor Necrosis Factor-alpha | 2 | 2025 | 1250 | 0.310 |
Why?
| | Inflammation | 4 | 2024 | 2902 | 0.280 |
Why?
| | Neutrophils | 2 | 2024 | 1282 | 0.260 |
Why?
| | Organoids | 3 | 2025 | 129 | 0.250 |
Why?
| | Ileum | 2 | 2024 | 112 | 0.240 |
Why?
| | Protein Kinase Inhibitors | 2 | 2024 | 919 | 0.240 |
Why?
| | Adaptation, Biological | 1 | 2025 | 54 | 0.230 |
Why?
| | Colitis | 2 | 2025 | 266 | 0.230 |
Why?
| | Tight Junction Proteins | 1 | 2024 | 15 | 0.220 |
Why?
| | Peroxidase | 1 | 2024 | 182 | 0.210 |
Why?
| | Bile Acids and Salts | 1 | 2024 | 151 | 0.200 |
Why?
| | Animals | 10 | 2025 | 37749 | 0.200 |
Why?
| | Cartilage Oligomeric Matrix Protein | 1 | 2021 | 3 | 0.180 |
Why?
| | Molecular Targeted Therapy | 1 | 2024 | 420 | 0.180 |
Why?
| | Deductibles and Coinsurance | 1 | 2021 | 12 | 0.170 |
Why?
| | Biological Evolution | 1 | 2025 | 493 | 0.170 |
Why?
| | Humans | 21 | 2025 | 141754 | 0.170 |
Why?
| | Piperidines | 2 | 2021 | 218 | 0.170 |
Why?
| | Mammals | 1 | 2022 | 287 | 0.170 |
Why?
| | Serine Endopeptidases | 1 | 2021 | 127 | 0.170 |
Why?
| | Myofibroblasts | 1 | 2022 | 128 | 0.170 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2022 | 288 | 0.160 |
Why?
| | Salmonella typhimurium | 1 | 2022 | 185 | 0.160 |
Why?
| | Pets | 1 | 2020 | 27 | 0.160 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2021 | 171 | 0.160 |
Why?
| | Disease Models, Animal | 3 | 2025 | 4421 | 0.160 |
Why?
| | Mice, Inbred C57BL | 3 | 2025 | 5909 | 0.150 |
Why?
| | Fecal Microbiota Transplantation | 1 | 2019 | 26 | 0.150 |
Why?
| | Stress, Mechanical | 1 | 2021 | 489 | 0.150 |
Why?
| | Irritable Bowel Syndrome | 1 | 2019 | 29 | 0.150 |
Why?
| | Clostridium Infections | 1 | 2020 | 74 | 0.150 |
Why?
| | Pyrimidines | 2 | 2021 | 512 | 0.150 |
Why?
| | Insurance, Health | 1 | 2021 | 299 | 0.140 |
Why?
| | Induction Chemotherapy | 1 | 2018 | 80 | 0.140 |
Why?
| | Fatty Liver | 1 | 2020 | 232 | 0.140 |
Why?
| | Mice | 6 | 2025 | 18109 | 0.140 |
Why?
| | Biological Products | 1 | 2021 | 239 | 0.140 |
Why?
| | Patient Acceptance of Health Care | 2 | 2022 | 881 | 0.140 |
Why?
| | Pyrroles | 1 | 2018 | 210 | 0.130 |
Why?
| | Life Style | 1 | 2020 | 482 | 0.130 |
Why?
| | Acute Disease | 1 | 2020 | 1010 | 0.130 |
Why?
| | Immunologic Factors | 1 | 2018 | 249 | 0.120 |
Why?
| | Liver | 2 | 2024 | 1820 | 0.120 |
Why?
| | Computer Simulation | 1 | 2020 | 1015 | 0.120 |
Why?
| | Computational Biology | 1 | 2020 | 664 | 0.110 |
Why?
| | Intracranial Aneurysm | 1 | 2016 | 100 | 0.110 |
Why?
| | Hypoxia | 1 | 2022 | 1165 | 0.110 |
Why?
| | Cognition Disorders | 2 | 2009 | 518 | 0.110 |
Why?
| | Feeding Behavior | 1 | 2020 | 682 | 0.100 |
Why?
| | Analgesics, Opioid | 1 | 2022 | 1123 | 0.100 |
Why?
| | Mutation | 1 | 2025 | 4015 | 0.100 |
Why?
| | Gastrointestinal Microbiome | 1 | 2019 | 730 | 0.090 |
Why?
| | Signal Transduction | 1 | 2024 | 5169 | 0.090 |
Why?
| | Alzheimer Disease | 2 | 2007 | 595 | 0.090 |
Why?
| | Biomarkers | 1 | 2021 | 4190 | 0.080 |
Why?
| | Dominance, Cerebral | 1 | 2007 | 56 | 0.070 |
Why?
| | Quality of Life | 1 | 2019 | 3014 | 0.060 |
Why?
| | Gyrus Cinguli | 1 | 2007 | 95 | 0.060 |
Why?
| | Brain Mapping | 1 | 2009 | 532 | 0.060 |
Why?
| | Brain | 2 | 2009 | 2868 | 0.060 |
Why?
| | Frontal Lobe | 1 | 2007 | 163 | 0.060 |
Why?
| | Image Processing, Computer-Assisted | 2 | 2007 | 774 | 0.060 |
Why?
| | Lactase | 1 | 2025 | 4 | 0.060 |
Why?
| | Xenobiotics | 1 | 2025 | 32 | 0.060 |
Why?
| | Pan troglodytes | 1 | 2025 | 66 | 0.060 |
Why?
| | Ileitis | 1 | 2024 | 32 | 0.050 |
Why?
| | Halogenation | 1 | 2024 | 23 | 0.050 |
Why?
| | Male | 10 | 2025 | 70179 | 0.050 |
Why?
| | Dextran Sulfate | 1 | 2024 | 85 | 0.050 |
Why?
| | Cholangitis, Sclerosing | 1 | 2024 | 56 | 0.050 |
Why?
| | Enhancer Elements, Genetic | 1 | 2025 | 189 | 0.050 |
Why?
| | Tight Junctions | 1 | 2024 | 78 | 0.050 |
Why?
| | Cerebral Cortex | 1 | 2007 | 462 | 0.050 |
Why?
| | Imaging, Three-Dimensional | 1 | 2007 | 569 | 0.050 |
Why?
| | Ustekinumab | 1 | 2023 | 17 | 0.050 |
Why?
| | Case-Control Studies | 2 | 2021 | 3597 | 0.050 |
Why?
| | Liver Cirrhosis | 1 | 2024 | 282 | 0.050 |
Why?
| | Motivation | 1 | 2007 | 603 | 0.050 |
Why?
| | Lipid Metabolism | 1 | 2025 | 528 | 0.050 |
Why?
| | Severity of Illness Index | 2 | 2020 | 2903 | 0.040 |
Why?
| | Retrospective Studies | 4 | 2021 | 16374 | 0.040 |
Why?
| | Female | 9 | 2025 | 75943 | 0.040 |
Why?
| | Evolution, Molecular | 1 | 2025 | 510 | 0.040 |
Why?
| | Aniline Compounds | 1 | 2022 | 120 | 0.040 |
Why?
| | Cognition | 1 | 2009 | 1228 | 0.040 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2022 | 557 | 0.040 |
Why?
| | Cell Adhesion | 1 | 2022 | 469 | 0.040 |
Why?
| | Colectomy | 1 | 2021 | 107 | 0.040 |
Why?
| | Prospective Studies | 2 | 2023 | 7777 | 0.040 |
Why?
| | Risk Assessment | 2 | 2019 | 3508 | 0.030 |
Why?
| | Magnetic Resonance Imaging | 2 | 2007 | 3737 | 0.030 |
Why?
| | Sulfonamides | 1 | 2022 | 567 | 0.030 |
Why?
| | Mice, Knockout | 1 | 2024 | 3071 | 0.030 |
Why?
| | Aged, 80 and over | 3 | 2020 | 7923 | 0.030 |
Why?
| | Phenotype | 1 | 2025 | 3177 | 0.030 |
Why?
| | Cerebral Angiography | 1 | 2016 | 115 | 0.030 |
Why?
| | Chronic Disease | 1 | 2021 | 1820 | 0.030 |
Why?
| | Cells, Cultured | 1 | 2022 | 4212 | 0.030 |
Why?
| | Middle Aged | 4 | 2020 | 34647 | 0.030 |
Why?
| | Treatment Outcome | 2 | 2019 | 11181 | 0.030 |
Why?
| | Hospitals | 1 | 2018 | 696 | 0.030 |
Why?
| | Prevalence | 1 | 2020 | 2799 | 0.030 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2019 | 1634 | 0.020 |
Why?
| | Hospitalization | 1 | 2022 | 2264 | 0.020 |
Why?
| | Population Surveillance | 1 | 2016 | 482 | 0.020 |
Why?
| | Young Adult | 2 | 2020 | 13749 | 0.020 |
Why?
| | Aged | 4 | 2020 | 24746 | 0.020 |
Why?
| | Emergency Service, Hospital | 1 | 2022 | 2193 | 0.020 |
Why?
| | Prognosis | 1 | 2019 | 4080 | 0.020 |
Why?
| | Cohort Studies | 1 | 2020 | 5815 | 0.020 |
Why?
| | Demography | 1 | 2009 | 296 | 0.020 |
Why?
| | Fluorodeoxyglucose F18 | 1 | 2009 | 147 | 0.020 |
Why?
| | Disease Progression | 1 | 2016 | 2800 | 0.020 |
Why?
| | Surface Properties | 1 | 2009 | 414 | 0.020 |
Why?
| | Positron-Emission Tomography | 1 | 2009 | 310 | 0.020 |
Why?
| | Atrophy | 1 | 2007 | 197 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2016 | 5212 | 0.020 |
Why?
| | Statistics as Topic | 1 | 2007 | 302 | 0.020 |
Why?
| | Adult | 2 | 2020 | 39391 | 0.020 |
Why?
| | Reference Values | 1 | 2007 | 807 | 0.010 |
Why?
| | Data Interpretation, Statistical | 1 | 2007 | 377 | 0.010 |
Why?
| | Models, Neurological | 1 | 2007 | 251 | 0.010 |
Why?
| | Time Factors | 1 | 2016 | 6966 | 0.010 |
Why?
| | Neuropsychological Tests | 1 | 2007 | 1093 | 0.010 |
Why?
| | Risk Factors | 1 | 2016 | 10482 | 0.010 |
Why?
| | Adolescent | 1 | 2020 | 22130 | 0.010 |
Why?
|
|
Steiner's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|